Boundless Bio, Inc. (NASDAQ: BOLD) is a Healthcare company (Biotechnology) with a market capitalization of $57M. The Maz Rating grades it against the other companies in its sector.
Boundless Bio, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.41, Boundless Bio, Inc. trades at 0.9x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -71.0%, return on invested capital of -95.7% and a free cash flow yield of -100.5%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 33.97. Over the past 52 weeks the share price ranged from $0.96 to $3.16, with a beta of 0.38.
Boundless Bio, Inc. does not currently pay a dividend.
20 Wall Street analyst ratings cover the stock: 6 Buy, 13 Hold and 1 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Boundless Bio, Inc. (BOLD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 106.2% / 30% · Interest income / Revenue 57200000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 106.2% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 57200000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 106.2% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 57200000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 10.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 77.2% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 57200000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 98.9% / 33.33% · (Cash+Recv) / Total Assets 98.9% / 33.33% · Interest income / Revenue 57200000.0% / 5% | Fail |
No. As of September 2026, Boundless Bio, Inc. (BOLD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Boundless Bio, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 57200000.0% of each dividend: Boundless Bio, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.